Quantcast

Latest Prostate cancer Stories

2014-04-14 23:08:01

A recent published review of the link between Actos and bladder cancer suggests that a federal jury’s judgment against the drug’s manufacturer is justified. Raleigh, NC (PRWEB) April 14, 2014 Earlier this week, a jury awarded $9 billion in punitive damages to a man who says he got bladder cancer from taking the diabetes drug Actos. (Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al, No. 6:12-cv-00064) According to cancer information site Cancer Monthly,...

2014-04-13 23:01:22

Days after a federal jury announced a $9 billion dollar judgment against the drug’s manufacturers, Cancer Monthly is encouraging bladder cancer patients to know their rights. Raleigh, NC (PRWEB) April 13, 2014 The Japanese manufacturer of the diabetes drug Actos and its partner firm, Eli Lilly & Co., have been ordered to pay $9 billion to Terrence Allen, who was diagnosed with bladder cancer after taking Actos. (Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc.,...

2014-04-12 23:01:34

A Louisiana jury’s decision to award $9 billion in damages to a man who says his bladder cancer was caused by the drug Actos could pave a new legal path for other bladder cancer patients. Raleigh, NC (PRWEB) April 12, 2014 Bladder cancer patients who took the drug Actos to control diabetes may now be able to establish a legal nexus or connection between the drug and the disease, thanks to a high-profile legal decision made this week.* If you are a bladder cancer patient who took Actos,...

2014-04-12 23:00:02

ResearchMoz.us include new market research report "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" to its huge collection of research reports.Full Report With TOC at http://www.researchmoz.us/metastatic-hormone-refractory-castration-resistant-androgen-independent-prostate-cancer-pipeline-review-h1-2014-report.html. Albany, NY (PRWEB) April 13, 2014 Researchmoz presents this most up-to-date research on...

2014-04-11 11:57:29

Most breast cancers are treated by blocking their addictions, for example depriving estrogen-fueled tumors of estrogen. But what about breast cancers without these hormonal addictions? In so-called "triple negative" tumors the cancer's addiction remains a mystery, making this subtype difficult to treat. However, a University of Colorado Cancer Center study presented today at the American Association for Cancer Research (AACR) Annual Meeting 2014 showcased a new drug active against...

2014-04-11 08:24:36

SAN DIEGO, April 11, 2014 /PRNewswire/ -- GenomeDx Biosciences announced today that two study abstracts for the company's genomic tests for prostate and bladder cancers have been selected as "Best Posters in a Poster Session" by conference organizers at the 29(th) Annual European Association of Urology Congress. The first poster presentation demonstrates the clinical validation of the Decipher® prostate cancer classifier for predicting treatment failure in men treated with...

2014-04-10 08:28:33

DUBLIN, April 10, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/qxfqmk/drug_delivery_in) has announced the addition of a new report "Drug Delivery in Cancer - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/qxfqmk/drug_delivery_in ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Drug delivery remains a challenge in management of cancer. Approximately 12.5...

2014-04-09 23:25:06

Biochemical testing suggests a pair of proteins can find and monitor bladder cancer better than standard techniques. Raleigh, NC (PRWEB) April 09, 2014 A team of Egyptian biochemists say angiogenin and clusterin – two proteins vital to certain cellular processes – could make bladder cancer diagnosis more accurate and treatments more effective. Click here to read details on the study which has just been posted on the Cancer Monthly website. Researchers with the Faculty of...

2014-04-09 08:28:15

SANTA ROSA, Calif., April 9, 2014 /PRNewswire/ -- A new study shows that honokiol, a small molecule polyphenol extract derived from Magnolia officinalis bark, reduces proliferation of renal cell carcinoma. Conducted by researchers at the Cancer Research Laboratory at Indiana University Health, Indiana University School of Medicine, the preclinical study showed that honokiol (HonoPure®, EcoNugenics, Santa Rosa, CA) inhibited two highly aggressive renal cell carcinoma (RCC) cell lines....

2014-04-08 12:30:37

-- Peak US urology organisation CUSP Group, LLC to evaluate MiStat(TM) technology SYDNEY, April 8, 2014 /PRNewswire/ -- Private Australian biotechnology company Minomic International Ltd will launch two overseas trials of its MiStat(TM) prostate cancer screening test, following an agreement with the prestigious CUSP Group, LLC a Uro-Oncology Trials Management Organisation in the United States. An initial pilot study to be launched in April will examine 300 patient samples and is...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.